-The outsourcing of large pharmaceutical companies’ research programmes encounters growing difficulties
-Pace of innovation in biotech and pharma could decline considerably
-Biotech SME platform offers support for financing

The biotech industry is being hit twice as hard by the economic crisis. In addition to the general economic downturn, the largely dried-up equity market, which has massively complicated the usual equity financing through the stock exchange or venture capital, is causing problems for companies.

The workshop ‘Water for Integration – Integration for Water’ took place in Brussels on September 28, 2009. This event provided a platform for participants from different sectors to discuss barriers and needs relating to integrated water research. The workshop was organized by

On the eve of her departure as EU Competition Commissioner, Mrs Neelie Kroes is apparently pushing to commit her successor and the entire future EU Commission into setting up a legal framework that will use litigation as the privileged mechanism of collective redress. Commented Orgalime Director General, Adrian Harris: “We are deeply concerned that the Commission is even considering introducing such a measure which is so alien to our legal traditions and not, as far as we can see, supported either by politicians or by industry. Quite the contrary.

• Economic programmes for cushioning the problems in healthcare largely unsuitable

• Shrinking GDP, rising unemployment and declining private insurance payments threaten the financing of healthcare systems

• Differences in the quality of healthcare for various social classes becoming considerably bigger

30/09/2009

In view of the catastrophic situation facing EU dairy farmers, EU farm leaders would like to invite you to a press conference on October 5 at Residence Palace at 13.00 h to discuss measures to help alleviate the drastic market situation. This will be followed by a buffet lunch.